Abstract
In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
Lingua originale | English |
---|---|
pagine (da-a) | N/A-N/A |
Rivista | GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA |
Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- actinic keratosis
- imiquimod